0  -8%
Previous Close 3.54
Open 4.00
Price To book 6.00
Market Cap 53.59M
Shares 16,488,000
Volume 1,021,549
Short Ratio 4.81
Av. Daily Volume 316,795

SEC filingsSee all SEC filings

  1. 8-K - Current report 17778797
  2. 8-K - Current report 17770289
  3. S-1 - General form for registration of securities under the Securities Act of 1933 17744511
  4. 8-K - Current report 17739716
  5. 8-K - Current report 17716019

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 to be initiated 2H 2017.
Chronic rhinosinusitis (CRS)

Latest News

  1. APHB: Looking to Follow-up on a Successful 2016
  2. AmpliPhi Biosciences Announces Presentation of Personalized Bacteriophage Therapy Case Study for Life-Threatening Antibiotic-Resistant Infection at Scientific Conference
  3. AmpliPhi Biosciences Review of Recent FDA Feedback and Drug Pipeline
  4. AmpliPhi Biosciences Announces Positive Feedback from FDA on Phase 2 Development Proposal
  5. AmpliPhi Biosciences Announces Planned One-for-Ten Reverse Stock Split
  6. AmpliPhi Biosciences Announces Presentations of Clinical and Preclinical Data from Studies with its Bacteriophage Technology at Two Scientific Conferences
  7. AmpliPhi Biosciences Corp. :APHB-US: Earnings Analysis: Q4, 2016 By the Numbers : March 29, 2017
  8. AmpliPhi Biosciences Reports 2016 Fourth-Quarter and Full-Year Results and Provides Corporate Highlights
  9. AmpliPhi Biosciences to Present at the 29th Annual ROTH Investor Conference
  10. AmpliPhi Biosciences Establishes Scientific Advisory Board and Appoints Dr. Timothy Lu of MIT and Broad Institute as SAB Chairman
  11. AmpliPhi Biosciences to Present at the 19th Annual BIO CEO and Investor Conference
  12. AmpliPhi Biosciences Appoints Dr. Igor P. Bilinsky as Senior Vice President and Chief Operating Officer
  13. Research Reports Coverage on Biotech Stocks -- OncoGenex Pharma, INSYS Therapeutics, Threshold Pharma, and AmpliPhi Biosciences
  14. Renowned Sinus Surgeon Dr. Peter-John Wormald Comments on AmpliPhi Biosciences’ Favorable Phase 1 Results of AB-SA01 in Chronic Rhinosinusitis Patients
  15. ETFs with exposure to AmpliPhi Biosciences Corp. : December 22, 2016
  16. AmpliPhi Biosciences Reports Favorable Final Results From Phase 1 Trial of AB-SA01 in Chronic Rhinosinusitis Patients
  17. CORRECTING and REPLACING AmpliPhi Biosciences Reports Favorable Final Results From Phase 1 Trial of AB-SA01
  18. AmpliPhi Biosciences Announces Pricing of Public Offering of Common Stock and Warrants
  19. AmpliPhi Biosciences Granted Small and Medium Enterprise Status by European Medicines Agency
  20. AmpliPhi Biosciences Appoints Dr. Carrie-Lynn Langlais Furr as Vice President of Regulatory Affairs and Program Management